Published by Josh White on 20th January 2026
(Sharecast News) - Avacta Group reported strong operational progress during 2025 on Tuesday as the clinical-stage biopharmaceutical company advanced its preCISION tumour-activated oncology platform, strengthened its intellectual property estate and secured additional funding to support the transition of a second programme into the clinic in 2026.